Low-dose rivaroxaban for CAD/PAD, hypertensio...
Oxygen supplementation, PCSK9 inhibitor prici...
CV outcomes in patients with type 2 diabetes,...
ODYSSEY PCSK9 inhibitor trial in print, new b...
The top 5 studies from the recent American He...
TAVR vs surgery for high-risk aortic stenosis...
Measures of hospital quality, statin under- o...
Carotid stents, more stem-cell retractions, A...
Dr John Mandrola discusses upcoding for PCI, ...
The cost of treating high blood pressure, hea...